$ACHV
ACHIEVE LIFE SCIENCES, INC. Stock $achv

$achv Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000156459019007838 Filed on March 14, 2019

Income Statement

Concept	2019 Q1	2018	2017 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.890M	$6.950M	$1.630M
YoY Change	4.42%	96.88%	-29.13%
% of Gross Profit
Research & Development	$4.055M	$5.868M	$2.153M
YoY Change	237.64%	89.23%	2591.25%
% of Gross Profit
Depreciation & Amortization	$70.00K	$60.00K	$90.00K
YoY Change	-22.22%	1.69%	125.0%
% of Gross Profit
Operating Expenses	$4.055M	$5.868M	$2.153M
YoY Change	237.64%	89.23%	2591.25%
Operating Profit
YoY Change
Interest Expense	$60.00K	$170.0K	$10.00K
YoY Change	500.0%	750.0%	-75.0%
% of Operating Profit
Other Income/Expense, Net	$36.00K	-$45.00K	$42.00K
YoY Change	-550.0%	-99.36%	-1150.0%
Pretax Income	-$5.900M	-$12.69M	-$3.740M
YoY Change	95.23%	-6.95%	-35.96%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.904M	-$12.69M	-$3.740M
YoY Change	95.37%	19.88%	669.55%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$17.35M	-$70.50M	-$62.33M
COMMON SHARES
Basic Shares Outstanding	6.721M		11.95M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.700M	$14.60M	$5.300M
YoY Change	130.95%	176.52%	-48.27%
Cash & Equivalents	$7.370M	$9.520M	$5.284M
Short-Term Investments	$2.300M	$5.090M
Other Short-Term Assets	$900.0K	$930.0K	$600.0K
YoY Change	50.0%	52.46%	-40.0%
Inventory
Prepaid Expenses			$393.0K
Receivables		$10.00K	$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$10.50M	$15.54M	$5.900M
YoY Change	121.24%	162.94%	32677.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$500.0K	$40.00K	$100.0K
YoY Change	2677.78%	-33.33%	-66.67%
Goodwill			$1.034M
YoY Change			0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$170.0K	$400.0K
YoY Change	-25.93%	-52.78%	33.33%
Total Long-Term Assets	$4.000M	$3.540M	$3.992M
YoY Change	6.55%	-11.06%	5.36%
TOTAL ASSETS
Total Short-Term Assets	$10.50M	$15.54M	$5.900M
Total Long-Term Assets	$4.000M	$3.540M	$3.992M
Total Assets	$14.50M	$19.08M	$9.892M
YoY Change	70.59%	92.92%	159.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$700.0K	$140.0K	$213.0K
YoY Change	75.0%	-33.33%	124.21%
Accrued Expenses	$3.300M	$3.130M	$1.800M
YoY Change	73.68%	76.84%	-70.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$4.000M	$3.270M	$2.013M
YoY Change	73.91%	62.69%	-34.49%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$300.0K	$10.00K
YoY Change
Total Long-Term Liabilities	$300.0K	$10.00K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.000M	$3.270M	$2.013M
Total Long-Term Liabilities	$300.0K	$10.00K	$0.00
Total Liabilities	$4.300M	$3.280M	$2.013M
YoY Change	85.5%	63.18%	-37.03%
SHAREHOLDERS EQUITY
Retained Earnings			-$12.69M
YoY Change			515.62%
Common Stock			$20.57M
YoY Change			662.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.19M	$15.80M	$15.80M
YoY Change
Total Liabilities & Shareholders Equity	$14.50M	$19.08M	$9.892M
YoY Change	71.39%	92.92%	159.84%

Cashflow Statement

Concept	2019 Q1	2018	2017 Q4
OPERATING ACTIVITIES
Net Income	-$5.904M	-$12.69M	-$3.740M
YoY Change	95.37%	19.88%	669.55%
Depreciation, Depletion And Amortization	$70.00K	$60.00K	$90.00K
YoY Change	-22.22%	1.69%	125.0%
Cash From Operating Activities	-$4.889M	-$10.62M	-$3.630M
YoY Change	118.94%	16.65%	-47.99%
INVESTING ACTIVITIES
Capital Expenditures	$54.00K	$46.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$2.740M	-$5.080M	$270.0K
YoY Change	27300.0%	-140.16%	-97.41%
Cash From Investing Activities	$2.690M	-$5.125M	$270.0K
YoY Change	26800.0%	-140.52%	-97.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	19.76M	890.0K
YoY Change	-100.0%	887.36%
NET CHANGE
Cash From Operating Activities	-4.889M	-10.62M	-3.630M
Cash From Investing Activities	2.690M	-5.125M	270.0K
Cash From Financing Activities	0.000	19.76M	890.0K
Net Change In Cash	-2.195M	4.009M	-2.470M
YoY Change	96.16%	-27.65%	-171.8%
FREE CASH FLOW
Cash From Operating Activities	-$4.889M	-$10.62M	-$3.630M
Capital Expenditures	$54.00K	$46.00K
Free Cash Flow	-$4.943M	-$10.67M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-581.25
CY2018Q4	achv	Working Capital Balance WorkingCapitalBalance	12300000
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6721200
CY2018Q2	dei	Entity Public Float EntityPublicFloat	15058692
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9515000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5284000
CY2017Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	222000
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	5089000
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	926000
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	393000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2310000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2532000
CY2018Q4	us-gaap	Goodwill Goodwill	1034000
CY2017Q4	us-gaap	Goodwill Goodwill	1034000
CY2018Q4	us-gaap	Assets Assets	19084000
CY2017Q4	us-gaap	Assets Assets	9892000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	144000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	213000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	748000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	438000
CY2018Q4	achv	Accrued Liabilities Clinical Current AccruedLiabilitiesClinicalCurrent	1199000
CY2017Q4	achv	Accrued Liabilities Clinical Current AccruedLiabilitiesClinicalCurrent	877000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1168000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	458000
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	11000
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	27000
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	579
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	579
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6721117
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1195675
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6721117
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1194793
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5868000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3101000
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2123
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	286000
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6945000
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3531000
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1428000
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	1714000
CY2017	us-gaap	Business Combination Bargain Purchase Gain Recognized Amount BusinessCombinationBargainPurchaseGainRecognizedAmount	1272000
CY2017	achv	Contingent Value Rights Recovery ContingentValueRightsRecovery	200000
CY2017	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-8610000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-35000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-24000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12687000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13634000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1738000
CY2017	achv	Recovery Of Deferred Income Taxes RecoveryOfDeferredIncomeTaxes	-3051000
CY2016	achv	Recovery Of Deferred Income Taxes RecoveryOfDeferredIncomeTaxes	-504000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-1234000
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	4000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	1840000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	610000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	348000
CY2017	achv	Settlement Of Stockholder Loans With Related Parties SettlementOfStockholderLoansWithRelatedParties	2132000
CY2017	achv	Shares Issued Under Common Stock Subscription Value SharesIssuedUnderCommonStockSubscriptionValue	64000
CY2017	achv	Combined Shares Held By Equity Holders CombinedSharesHeldByEquityHolders	3000
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	13048000
CY2017	achv	Stock Issued During Period Value Restricted Stock Unit Settlements Withheld And Retired To Treasury StockIssuedDuringPeriodValueRestrictedStockUnitSettlementsWithheldAndRetiredToTreasury	5000
CY2017	achv	Purchase Accounting Adjustments PurchaseAccountingAdjustments	44000
CY2018	achv	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1324000
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1000
CY2018	us-gaap	Profit Loss ProfitLoss	-12687000
CY2017	us-gaap	Profit Loss ProfitLoss	-10583000
CY2016	us-gaap	Profit Loss ProfitLoss	-1234000
CY2018	us-gaap	Depreciation Depreciation	60000
CY2017	us-gaap	Depreciation Depreciation	59000
CY2018	us-gaap	Adjustment For Amortization AdjustmentForAmortization	222000
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	223000
CY2016	us-gaap	Adjustment For Amortization AdjustmentForAmortization	223000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	854000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	348000
CY2017	achv	Contingent Value Rights Liability Recovery ContingentValueRightsLiabilityRecovery	200000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	343000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1349000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9107000
CY2018	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-69000
CY2017	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	118000
CY2016	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	22000
CY2018	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	310000
CY2017	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2185000
CY2016	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	670000
CY2018	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	322000
CY2017	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	877000
CY2016	achv	Interest Expense Accrued But Not Yet Paid InterestExpenseAccruedButNotYetPaid	26000
CY2018	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	710000
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	458000
CY2017	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	-1028000
CY2016	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	623000
CY2018	achv	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	4000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5541000
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-52000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5556000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15000
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	67000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9565000
CY2017	achv	Increase Decrease In Lease Obligations IncreaseDecreaseInLeaseObligations	-27000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10623000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19757000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2001000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	150000
CY2017	achv	Cash Assumed In Reverse Merger CashAssumedInReverseMerger	12648000
CY2018	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	10000
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5539000
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	450000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5125000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12648000
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4009000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-202000
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	64000
CY2018	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1279000
CY2017	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	1942000
CY2018	achv	Proceeds From Public Offering ProceedsFromPublicOffering	12194000
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1324000
CY2018	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4960000
CY2016	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	150000
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and notes thereto. Actual results could differ from these estimates. Estimates and assumptions principally relate to estimates of the fair value of our warrant liability, the initial fair value and forfeiture rates of stock options issued to employees and consultants, the estimated compensation cost on performance restricted stock unit awards, clinical trial and manufacturing accruals, estimated useful lives of property, plant, equipment and intangible assets, estimates and assumptions in contingent liabilities. </p>
CY2018Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1
CY2018Q4	achv	Number Of Products Approved For Commercial Sale NumberOfProductsApprovedForCommercialSale	0
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0
CY2018	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	us-gaap:ProductMember
CY2018Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	14600000
CY2018	achv	Maturity Period Of Highly Liquid Investments To Be Considered As Cash Equivalent MaturityPeriodOfHighlyLiquidInvestmentsToBeConsideredAsCashEquivalent	P3M
CY2018	achv	Description Of Maturity Period Of Financial Instruments To Be Considered As Short Term Investment DescriptionOfMaturityPeriodOfFinancialInstrumentsToBeConsideredAsShortTermInvestment	Greater than three months and less than one year
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2018	achv	Average Period To Maturity For Portfolio Of Cash And Marketable Securities AveragePeriodToMaturityForPortfolioOfCashAndMarketableSecurities	P0D
CY2017Q3	us-gaap	Finite Lived Intangible Assets Fair Value Disclosure FiniteLivedIntangibleAssetsFairValueDisclosure	8600000
CY2017Q3	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P6Y
CY2015Q2	us-gaap	Finite Lived Intangible Assets Fair Value Disclosure FiniteLivedIntangibleAssetsFairValueDisclosure	3100000
CY2015Q2	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P14Y
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	200000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	223000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	223000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	223000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	223000
CY2018Q4	achv	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	1418000
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8000
CY2018Q4	us-gaap	Costs And Expenses CostsAndExpenses	3709000
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8000
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1045000
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1541000
CY2018Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2081000
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1813000
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1751000
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1753000
CY2018Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1628000
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	3014000
CY2018Q2	us-gaap	Costs And Expenses CostsAndExpenses	2796000
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	3294000
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	54000
CY2018Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	72000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-3022000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-2788000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-3240000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-3637000
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.43
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.82
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.55
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61000
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	62000
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	825000
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	260000
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	96000
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1546000
CY2017Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1629000
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	321000
CY2017Q2	us-gaap	Costs And Expenses CostsAndExpenses	158000
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	2371000
CY2017Q4	us-gaap	Costs And Expenses CostsAndExpenses	3782000
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8000
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11000
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7025000
CY2017Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	42000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-205000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-169000
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-96.56
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2018Q4	us-gaap	Cash Cash	1070000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	50000
CY2017Q4	us-gaap	Cash Cash	1262000
CY2018	achv	Maximum Maturity Period Of Cash And Cash Equivalents MaximumMaturityPeriodOfCashAndCashEquivalents	P90D
CY2018	achv	Maximum Maturity Period Of Short Term Investments MaximumMaturityPeriodOfShortTermInvestments	P1Y
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	755000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	720000
CY2018	achv	Period Of Not Utilizing Deferred Share Issuance Costs And Prepaid Amounts Related To Insurance PeriodOfNotUtilizingDeferredShareIssuanceCostsAndPrepaidAmountsRelatedToInsurance	P12M
CY2018	achv	Future Income Tax Rate Assumed For Deferred Tax Calculations FutureIncomeTaxRateAssumedForDeferredTaxCalculations	0.21
CY2017	achv	Future Income Tax Rate Assumed For Deferred Tax Calculations FutureIncomeTaxRateAssumedForDeferredTaxCalculations	0.34
CY2016	achv	Future Income Tax Rate Assumed For Deferred Tax Calculations FutureIncomeTaxRateAssumedForDeferredTaxCalculations	0.34
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2664000
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4636000
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-504000
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	70000
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-174000
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-1416000
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	3158000
CY2018	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-165000
CY2017	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	314000
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4182000
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1683000
CY2018	achv	Income Tax Reconciliation Book To Tax Return Adjustments IncomeTaxReconciliationBookToTaxReturnAdjustments	20000
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-27000
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-14000
CY2017	achv	Income Tax Expense Benefit Excluding Adjustment For Reversal Of Deferred Tax Liability IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability	-3035000
CY2016	achv	Income Tax Expense Benefit Excluding Adjustment For Reversal Of Deferred Tax Liability IncomeTaxExpenseBenefitExcludingAdjustmentForReversalOfDeferredTaxLiability	-504000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	17600000
CY2017Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	9900000
CY2018	achv	Unclaimed Tax Deductions Related To Scientific Research And Experimental Development Expenditures UnclaimedTaxDeductionsRelatedToScientificResearchAndExperimentalDevelopmentExpenditures	14500000
CY2018Q4	achv	Deferred Tax Assets Capitalized Research And Development Expenses DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses	3334000
CY2017Q4	achv	Deferred Tax Assets Capitalized Research And Development Expenses DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses	3252000
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	474000
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	513000
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	3000
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2000
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	477000
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	515000
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	715000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	715000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	699000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	16000
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	4000
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	717000
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	700000
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2018Q2	achv	Class Of Warrant Or Right Exercise Period ClassOfWarrantOrRightExercisePeriod	P5Y
CY2018Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.00
CY2018	achv	Class Of Warrant Or Right Cancellation Description ClassOfWarrantOrRightCancellationDescription	Additionally, subject to certain exceptions, if, after the June 19, 2018, (i) the volume weighted average price of our common stock for each of 30 consecutive trading days, or the Measurement Period, which Measurement Period commences on June 19, 2018, exceeds 300% of the exercise price (subject to adjustments for stock splits, recapitalizations, stock dividends and similar transactions), (ii) the average daily trading volume for such Measurement Period exceeds $500,000 per trading day and (iii) certain other equity conditions are met, and subject to a beneficial ownership limitation, then we may call for cancellation of all or any portion of the warrants then outstanding.
CY2018Q2	achv	Number Of Required Consecutive Days Weighted Average Trading Price For Cancelation Or Recall Of Warrants NumberOfRequiredConsecutiveDaysWeightedAverageTradingPriceForCancelationOrRecallOfWarrants	P30D
CY2018Q2	achv	Minimum Required Trading Price Percentage Over Exercise Price For Cancelation Or Recall Of Warrants MinimumRequiredTradingPricePercentageOverExercisePriceForCancelationOrRecallOfWarrants	3.00
CY2018Q2	achv	Minimum Required Trading Volume Value Per Day For Cancelation Or Recall Of Warrants MinimumRequiredTradingVolumeValuePerDayForCancelationOrRecallOfWarrants	500000
CY2018	achv	Gross Proceeds From Sale Of Warrants And Units GrossProceedsFromSaleOfWarrantsAndUnits	13800000
CY2018	achv	Warrant And Units Offering Cost Including Underwriting Discounts And Commissions WarrantAndUnitsOfferingCostIncludingUnderwritingDiscountsAndCommissions	1600000
CY2018	achv	Net Proceeds From Sale Of Warrants And Units NetProceedsFromSaleOfWarrantsAndUnits	12200000
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2018	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	5354
CY2017	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	546
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0293
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0195
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M4D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y7D
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8823
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8606
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.05
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	393
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	665585
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	80.01
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.81
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	160.79
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.65
CY2018Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	665585
CY2018Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	15.65
CY2018	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P9Y5M15D
CY2018Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	96615
CY2018Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	73.05
CY2018	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P8Y11M8D
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2400000
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2000000
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1000000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	600000
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0
CY2017	achv	Number Of Warrants Exercised NumberOfWarrantsExercised	0
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4700000
CY2018Q4	us-gaap	Contractual Obligation ContractualObligation	574000
CY2018Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	207000
CY2018Q4	us-gaap	Contractual Obligation Due In Second And Third Year ContractualObligationDueInSecondAndThirdYear	298000
CY2018Q4	us-gaap	Contractual Obligation Due In Fourth And Fifth Year ContractualObligationDueInFourthAndFifthYear	69000
CY2018	achv	Expiration Of Operating Lease Agreement ExpirationOfOperatingLeaseAgreement	2019-01
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	600000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000
CY2018Q4	us-gaap	Guarantee Obligations Current Carrying Value GuaranteeObligationsCurrentCarryingValue	0
CY2018	achv	Indemnification Expense IndemnificationExpense	0
CY2017Q3	achv	Number Of Terminated Senior Executives NumberOfTerminatedSeniorExecutives	1
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1201000
CY2017Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2153000
CY2017Q1	achv	Recovery Of Deferred Income Taxes RecoveryOfDeferredIncomeTaxes	-124000
CY2017Q3	achv	Recovery Of Deferred Income Taxes RecoveryOfDeferredIncomeTaxes	-2927000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-6469000
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-3740000
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-79.60
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-8.95
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.17

Files In Submission

Name	View Source	Status
0001564590-19-007838-index-headers.html	Edgar Link	pending
0001564590-19-007838-index.html	Edgar Link	pending
0001564590-19-007838.txt	Edgar Link	pending
0001564590-19-007838-xbrl.zip	Edgar Link	pending
achv-10k_20181231.htm	Edgar Link	pending
achv-20181231.xml	Edgar Link	completed
achv-20181231.xsd	Edgar Link	pending
achv-20181231_cal.xml	Edgar Link	unprocessable
achv-20181231_def.xml	Edgar Link	unprocessable
achv-20181231_lab.xml	Edgar Link	unprocessable
achv-20181231_pre.xml	Edgar Link	unprocessable
achv-ex1025_660.htm	Edgar Link	pending
achv-ex211_11.htm	Edgar Link	pending
achv-ex231_13.htm	Edgar Link	pending
achv-ex311_7.htm	Edgar Link	pending
achv-ex312_8.htm	Edgar Link	pending
achv-ex321_10.htm	Edgar Link	pending
achv-ex322_12.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gs4jg5aoeq1r000001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACHV
ACHIEVE LIFE SCIENCES, INC. Stock $achv

2019 Q1 Form 10-K Financial Statement

#000156459019007838 Filed on March 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACHV ACHIEVE LIFE SCIENCES, INC. Stock $achv

2019 Q1 Form 10-K Financial Statement

#000156459019007838 Filed on March 14, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACHV
ACHIEVE LIFE SCIENCES, INC. Stock $achv